Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK buys oral healthcare brand for $170 million

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline is buying Biotene, the top dry mouth brand, from privately held Laclede for $170 million to strengthen its therapeutic oral healthcare portfolio. John Clarke, president of GSK's consumer healthcare, says the move will leverage the company's global capability with dental and medical professionals and help diversify the company's healthcare business. The transaction is subject to regulatory review in the US and Europe, and is expected to be complete by early 2009. Global sales of Biotene grew by 17% to around $50 million in 2007; around 65% of its current sales are in the US. Dry mouth, also known as xerostomia, is a serious problem associated with chronic medical conditions such as diabetes, rheumatoid arthritis, Sjogren's and Parkinson's disease. It can also be a side-effect of chemotherapy or radiation treatment.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC022055

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel